🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07453381
Recruiting Observational

Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective, Multicenter, Single-Group Target Value Study

NCT07453381 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Observational
Started
2026-06-30
Last updated
2026-07-30

Condition(s) studied

Coronary Microvascular Dysfunction (CMD)

Study summary

This study aims to evaluate the sensitivity and specificity of a multi-sensor wireless pressure microcatheter for the diagnosis of CMD in patients with ANOCA/INOCA, using quantitative myocardial perfusion imaging of cardiac magnetic resonance (CMR) as a reference.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years, gender not limited; 2. Symptoms of angina pectoris, or objective evidence of myocardial ischemia (e.g., electrocardiogram, myocardial injury markers, etc.); 3. Visual assessment of coronary angiography shows diameter stenosis \< 50% and FFR \> 0.8 (or cRR \> 0.89); 4. Microvascular function assessment is planned; 5. Agree to participate in this clinical study and voluntarily sign the informed consent form. Exclusion Criteria: 1. Acute myocardial infarction, PCI, CABG, or valvular surgery following angiography within the past 30 days; 2. Severe valvular disease requiring surgical or interventional treatment; 3. Chest pain with known non-ischemic causes (e.g., pericarditis, pulmonary hypertension, esophageal spasm); 4. Contraindications to CMR (e.g., certain types of pacemakers or defibrillators, severe claustrophobia); 5. Clear contraindications to adenosine and ATP use (e.g., second- or third-degree atrioventricular block, sick sinus syndrome, severe asthma, systolic blood pressure below 90 mmHg); 6. Renal insufficiency (eGFR ≤ 45 mL/min/1.73 m2) or currently undergoing dialysis; 7. Severe heart failure or LVEF ≤ 35%; 8. Severe organ disease or life expectancy less than 2 years; 9. Known to be participating in other drug or device clinical trials that have not yet met the primary endpoint; 10. Other investigators deem the candidate unsuitable for this clinical trial.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Wang Jing Hospital Of CACMS(China Academy of Chinese Medical Sciences) Beijing Beijing Municipality Not Yet Recruiting
Cangzhou Central Hospital Cangzhou Hebei Not Yet Recruiting
Chengdu Second People's Hospital Chengdu Sichuan Not Yet Recruiting
Beijing Anzhen Hospital.Capital Medical University Beijing China Recruiting
Peking University Third Hospital Beijing China Recruiting

More Peking University Third Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07453381 on ClinicalTrials.gov ↗ ← All trials in China